Exactech, Inc. (EXAC) Stake Decreased by Falcon Point Capital LLC
Falcon Point Capital LLC cut its stake in shares of Exactech, Inc. (NASDAQ:EXAC) by 44.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 20,524 shares of the medical equipment provider’s stock after selling 16,328 shares during the quarter. Falcon Point Capital LLC’s holdings in Exactech were worth $1,015,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Pentwater Capital Management LP acquired a new position in shares of Exactech during the 4th quarter worth $12,363,000. Kassirer Asset Management Corp acquired a new position in shares of Exactech during the 4th quarter worth $1,746,000. Gamco Investors INC. ET AL grew its stake in shares of Exactech by 24.8% during the 4th quarter. Gamco Investors INC. ET AL now owns 764,508 shares of the medical equipment provider’s stock worth $37,805,000 after purchasing an additional 151,991 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Exactech during the 4th quarter worth $5,155,000. Finally, Gabelli Funds LLC grew its stake in shares of Exactech by 138.7% during the 4th quarter. Gabelli Funds LLC now owns 701,748 shares of the medical equipment provider’s stock worth $34,701,000 after purchasing an additional 407,724 shares during the period. 61.22% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have recently weighed in on the stock. Sidoti cut shares of Exactech from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. BidaskClub cut shares of Exactech from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 30th. Robert W. Baird reissued a “hold” rating and issued a $49.00 price objective on shares of Exactech in a research note on Thursday, December 7th. Zacks Investment Research cut shares of Exactech from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Finally, Gabelli cut shares of Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Six research analysts have rated the stock with a hold rating, The company presently has a consensus rating of “Hold” and an average target price of $49.00.
TRADEMARK VIOLATION NOTICE: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2018/02/14/exactech-inc-exac-stake-decreased-by-falcon-point-capital-llc.html.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.